USANA Health Sciences, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended January 2, 2021. Although the request metadata says “2019 Q4,” the supplied filing is for fiscal 2020, a 53-week year, compared principally with fiscal 2019, a 52-week year. The extra week contributed an estimated $18 million to 2020 sales.
Business context
USANA develops and sells nutritional, personal-care, and skincare products through direct selling in 24 markets. It reported approximately 599,000 active Customers at year-end, up 2.2%. Mainland China remained its largest individual market, with $470.2 million in sales, about 41% of consolidated net sales. Approximately 90.5% of sales were generated outside the United States.
Financial performance
| Metric | 2020 | 2019 | Change or context |
|---|---|---|---|
| Net sales | $1,134.6 million | $1,060.9 million | Up 7.0% reported; up 6.9% excluding currency impact |
| Gross profit | $925.5 million | $873.4 million | Gross margin was 81.6%, down from 82.3% |
| Operating earnings | $176.5 million | $146.2 million | Operating margin 15.6%, up from 13.8% |
| Net earnings | $124.7 million | $100.5 million | Up 24.0%; net margin 11.0%, versus 9.5% |
| Diluted EPS | $5.86 | $4.41 | Increase reflected higher earnings and a lower diluted share count |
| Operating cash flow | $160.4 million | $126.7 million | Up $33.7 million |
| Cash and cash equivalents | $311.9 million | $234.8 million | Year-end balances |
| Debt | No credit-facility balance | — | $75 million revolving facility; potential commitment increase of up to $200 million, subject to conditions |
Cost of sales rose to 18.4% of sales from 17.7%, reflecting sales mix, shipping, and production costs. Associate incentives were 43.0% of sales versus 43.3%. Selling, general and administrative costs fell to 23.0% of sales from 25.2%, partly due to lower event and travel spending. The effective tax rate declined to 29.9% from 33.2%, benefiting from use of previously unbenefited U.S. tax attributes.
Operating cash flow supported liquidity. Cash use included $57.0 million for share repurchases, a $20.0 million minority investment and collaboration with Built Brands, and $15.1 million of property and equipment purchases. Inventory increased to $90.2 million from $68.9 million, in part as a supply-chain precaution. Current assets were $425.3 million and current liabilities $168.1 million at year-end.
Material changes versus 2019
- Sales and earnings rebounded from 2019, when sales had declined. 2020 sales growth was supported by customer growth and sales initiatives, though the extra fiscal week contributed an estimated $18 million.
- Regional results diverged: Greater China sales fell 1.0% reported, while Southeast Asia Pacific rose 22.5%, North Asia 19.5%, and Americas and Europe 5.3%.
- Active Customers increased overall by 13,000. Greater China fell by 38,000 (13.1%), offset by growth in Southeast Asia Pacific, North Asia, and the Americas and Europe.
- Cash increased by $77.1 million. The company repurchased $57.0 million of shares in 2020, compared with $150.0 million in 2019; shares outstanding declined year over year.
- Gross margin weakened, but lower relative operating expenses and the lower tax rate lifted operating and net margins.
Outlook, risks and unusual items
- Outlook: Management provided no specific numerical revenue or earnings guidance in the supplied filing text. Plans include launching an Active Nutrition line beginning in the second quarter of 2021, expanding in-house food and skincare manufacturing, investing in digital customer experience, and preparing a new international market for a planned 2022 announcement.
- COVID-19: Management said the pandemic’s overall 2020 impact was not material, while describing disruption to in-person selling, events, some shipping and sourcing, and operations in certain markets. It expected pandemic-related effects to continue in 2021 and said their duration and magnitude remained uncertain.
- China exposure: China is a major source of revenue, and its direct-selling model has not been approved by the Chinese government. The government’s 2019 industry review suspended applications for new direct-selling authorizations; the filing says reopening timing is unknown. Regulatory action, fines, license restrictions, or business suspension could materially affect results.
- Other key risks: Direct-selling regulation and FTC scrutiny; Associate retention and conduct; foreign exchange; U.S.–China trade and political tensions; supply-chain and manufacturing disruption; product regulation and claims; data privacy and cybersecurity; and tax and transfer-pricing disputes.
- Debt and liquidity: The $75 million revolving facility matures in August 2025 and requires adjusted EBITDA of at least $100 million and a funded-debt-to-adjusted-EBITDA ratio no greater than 2.0 to 1.0. Management said liquidity was strong and expected operating cash flow to fund the business. Cash held in China may be subject to remittance timing and regulatory requirements.
- Capital allocation: The board increased the share-repurchase authorization to $150 million on February 9, 2021, inclusive of the approximately $73 million remaining at year-end. Subsequent to year-end through February 26, the company repurchased 284,000 shares for $26.4 million.
- Contingencies and audit: The company reported ordinary-course legal matters, including a 2020 California lawsuit seeking reclassification of Associates; management said it did not believe the matters would have a material adverse effect. The filing reports unqualified audit opinions and effective internal control over financial reporting. KPMG identified inventory valuation as a critical audit matter, involving estimates of future demand and excess or slow-moving inventory.
Most important facts for investors to verify
- How much of the 2020 sales and earnings improvement is sustainable after accounting for the extra fiscal week, promotions, pandemic-driven demand, and reduced travel and event costs.
- Whether customer losses and sales declines in Greater China stabilize, and whether Chinese regulators reopen license applications or change enforcement of direct-selling rules.
- Whether gross-margin pressures from shipping, production costs, and market mix persist, and whether new in-house manufacturing improves costs as planned.
- How much cash is available for U.S. corporate use versus held in China or other markets, including the timing and restrictions on repatriation.
- Whether share repurchases, the Built Brands investment, and planned expansion remain consistent with operating cash generation and the credit-facility covenants.